Studies have demonstrated that HHT markedly enhances the anti-myeloma efficacy of BTZ in both in vitro multiple myeloma (MM) cell models and in vivo mouse xenotransplantation models through inhibition of the NF-κB signaling pathway (48). The gene discussed is NFKB1; the disease is plasma cell myeloma.